PRObing The Efficacy of Commercial Stage Storage Buffers and Evaluating Gut Metaproteome Variability Between Individuals
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-70
SponsorUniversity of Vienna
About this trial
The study aims to assess the effectiveness of various commercial and non-hazardous buffers for the storage of human gut fecal samples over time. This evaluation will be conducted by comparing the performance of these buffers against directly frozen samples using metaproteomic analysis. The study is motivated by the need for standardized protocols for sample preservation in metaproteomic research, particularly focusing on protein preservation in fecal samples. By investigating proteomic, taxonomic, and functional identifications, the research seeks to provide insights into the reliability of these buffers as storage solutions. Additionally, the study plans to explore inter- and intra-individual variabilities at the proteome level by periodically collecting fecal samples from volunteers, complementing existing knowledge in metaproteomics. Overall, the study addresses a critical gap in the field and has the potential to enhance reproducibility and comparability across metaproteomic studies
Eligibility criteria
This trial accepts healthy volunteersQualifiers
agreeing to participate after signing the informed consent form and
being 18-70 years old.
Disqualifiers
take antibiotics during the previous 1 month
had undergone gastrointestinal surgery
Trial population
healthy volunteers (among the members of our laboratory/Division) will be recruited
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
52 Participants
are grouped into 2 trial groupsGroup A: storage buffer standardisation
Group B: inter- and intra-individual variability
Trial outcomes
Primary outcomes
1
Eggerthella abundance
Eggerthella abundance will be checked in to the Metaproteomic profile of each fecal samples and inter/intra-individual variability will be assessed
Time frame
From enrollment to the end of treatment at 4 weeksSecondary outcomes
1
Age
Age will be collected from each participant during the first interview
Time frame
From enrollment to the end of treatment at 4 weeks2
Sex
Sex will be collected from each participant during the first interview
Time frame
From enrollment to the end of treatment at 4 weeks3
Body Mass Index (BMI)
BMI will be collected from each participant during the first interview
Time frame
From enrollment to the end of treatment at 4 weeks4
Antibiotic use
Antibiotic use in the previous 1 month before the study enrollment, will be collected from each participant during the first interview
Time frame
From enrollment to the end of treatment at 4 weeksSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov